Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbbreviations
Ver el documento1. Summary
Abrir esta carpeta y ver su contenido2. Introduction
Abrir esta carpeta y ver su contenido3. Study design and methods
Ver el documento4. Results
Abrir esta carpeta y ver su contenido5. Discussion
Abrir esta carpeta y ver su contenido6. Conclusions and recommendations
Ver el documentoReferences
Cerrar esta carpetaAnnexes
Cerrar esta carpetaAnnex 1: Detailed results for each drug
Ver el documento1.1 Amoxycillin capsules
Ver el documento1.2 Ampicillin capsules
Ver el documento1.3 Acetylsalicylic acid tablets
Ver el documento1.4 Doxycycline capsules
Ver el documento1.5 Ferrous sulfate tablets
Ver el documento1.6 Phenoxymethylpenicillin tablets
Ver el documento1.7 Tetracycline capsules
Ver el documento1.8 Retinol tablets
Ver el documento1.9 Epinephrine injection
Ver el documento1.10 Ampicillin injection
Ver el documento1.11 Benzylpenicillin injection
Ver el documento1.12 Ergometrine injection
Ver el documento1.13 Procaine penicillin injection
Ver el documentoAnnex 2: Validation of laboratory results
 

1.4 Doxycycline capsules

SHELF LIFE

Manufacturer A: 2-3 years

ASSAY METHOD

In-house HPLC method Contents of 20 capsules mixed; measured three times; mean taken.

ASSAY LIMITS

90 - 120% (USP)

SAMPLES OBTAINED

Manufacturer A

GMS samples

no.

%

Total

5

100

Harare

2

40

Bulawayo

3

60

Facility samples

no.

%

Total

15

100

Age > 50% SLife

9

60

Facility type = PCH

0

0

Climate = hot

3

20

Transport = slow

10

67

Longitudinal series

   

Total

5

100

SUMMARY ASSAY RESULTS

GMS samples

Manufacturer A

Mean age (mths)

 

8.9

Mean assay

 

102.1%

95% CL

96.6 - 107.7%

No, and % fail

0

0%

Facility samples

Manufacturer A

Mean age (mths)

 

17.3

Mean assay

 

110.1%

95% CL

105.0 - 115.1%

No, and % fail

2

13%

No, and % low fail

1

7%

No, and % high fail

1

7%

Longitudinal series

at manufacturer

at GMS

at facility

Mean age (mths)

 

0

6.9

17.1

Mean assay

 

100.4%

104.9%

109.8%

95% CL

98.6 - 102.1 %

99.6-110.2%

106.1 - 113.5%

No. and % fail

0

0%

0

0%

0

0%

 

Mean interval (mths)

10.1

 

Mean loss (-) or gain (+)

+5.0%

 

95% CL for loss/gain

-2.0 to +11.9%


Figure 1 - Results of facility samples

Findings:

a) Five of 20 facility samples (26%) were expired; these results were excluded.

b) All five GMS samples were within assay limits (mean 102.1 %).

c) Two of 15 facility samples (13%) failed; one failure was below the lower limit (82.7%) at age 21.9 months.

One failure was above the upper limit (125.2%).

The mean facility assay tended towards the upper limit of specifications (110.1%),

d) No consistent loss of potency was found in five GMS/facility sample pairs.

e) Small sample size/wide confidence limits make interpretation difficult,

f) No initial quality problem was seen.

g) No evidence of instability, except one failure which may be due to a measurement error,

h) Three expired samples had a lower mean assay (97.8%) at mean age 27.7 months.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013